FAQ

refractory cancer

Known as: clinical resistance, resistant cancer, cancer refractory 
Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1944-2017
010020030019442016

Related topics

Related topics

2 relations
Neoplastic Cellcancer cell

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
refractory cancer
cancer cell
Neoplastic Cell

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Update of the Drug Resistance Mutations in HIV-1
This July 2014 edition of the IAS–USA drug resistance mutations list updates the figures last published in March 2013.1 The… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
The monoclonal antibodies (moAb) panitumumab and cetuximab target the epidermal growth factor receptor (EGFR) and have proven… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
Loss of PTEN function leads to activation of phosphoinositide 3-kinase (PI3K) signaling and Akt. Clinical trials are now testing… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are…
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have detectable BCR-ABL kinase domain… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
PURPOSE Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory cancer pain, but there are no… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
To reveal the antiangiogenic capability of cancer chemotherapy, we developed an alternative antiangiogenic schedule for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer…
PURPOSE To determine the toxicity, pharmacokinetics, response rate, and response duration of intravenous (i.v.) administration of… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
PURPOSE A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum… (More)
Is this relevant?
Highly Cited
1978
Highly Cited
1978
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
With a direct in vitro tumor-colony assay developed to measure sensitity of human-tumor stem cells to anticancer drugs, we… (More)
Is this relevant?